Last reviewed · How we verify
CL-197 capsules
CL-197 capsules are a small molecule that targets the SGLT2 receptor.
CL-197 capsules are a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | CL-197 capsules |
|---|---|
| Sponsor | Henan Genuine Biotech Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the SGLT2 receptor, CL-197 capsules reduce glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes. CL-197 capsules have shown promise in phase 2 clinical trials for this indication.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A Phase Ⅱa Clinical Study of CL-197 Capsules (PHASE2)
- A Study of CL-197 Capsules in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CL-197 capsules CI brief — competitive landscape report
- CL-197 capsules updates RSS · CI watch RSS
- Henan Genuine Biotech Co., Ltd. portfolio CI